000136916 001__ 136916
000136916 005__ 20240229105106.0
000136916 0247_ $$2doi$$a10.1186/s12916-018-1120-9
000136916 0247_ $$2pmid$$apmid:30126408
000136916 0247_ $$2pmc$$apmc:PMC6102804
000136916 0247_ $$2altmetric$$aaltmetric:46769229
000136916 037__ $$aDKFZ-2018-01354
000136916 041__ $$aeng
000136916 082__ $$a610
000136916 1001_ $$0P:(DE-He78)448ff49e51672d79b4747339ac15c898$$aHuang, Lei$$b0$$eFirst author$$udkfz
000136916 245__ $$aStratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study.
000136916 260__ $$aLondon$$bBioMed Central$$c2018
000136916 3367_ $$2DRIVER$$aarticle
000136916 3367_ $$2DataCite$$aOutput Types/Journal article
000136916 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659949842_8494
000136916 3367_ $$2BibTeX$$aARTICLE
000136916 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136916 3367_ $$00$$2EndNote$$aJournal Article
000136916 520__ $$aThe prognosis of pancreatic cancer (PaC) strongly varies across different stages and age groups, which has unfortunately not been well recorded in the literature. This international population-based study aimed to provide tumor-node-metastasis (TNM) stage- and age-specific survival estimates and trends in resected and overall (resected and unresected) PaC in the early twenty-first century.Using data from the US Surveillance, Epidemiology, and End Results-18 Program and the national cancer registries of the Netherlands, Belgium, Norway, and Slovenia, short-term and long-term overall survival results stratified by TNM stage and age in resected and overall primary PaC, irrespective of being microscopically confirmed or not, in 2003-2014 were computed using the Kaplan-Meier method. The temporal survival trends over three predefined periods (2003-2005, 2006-2008, and 2009-2011) were further examined using the log-rank test.In total, data for 125,183 patients were analyzed. Overall, age-stratified 3-year survival was 20-34% (< 60 years), 14-25% (60-69 years), and 9-13% (≥ 70 years) in stages I-II PaC; and 2-5% (< 60 years), 1-2% (60-69 years), and < 1-1% (≥ 70 years) in stages III-IV cancer. Patients who underwent operation had higher 3-year survival in each stage and age group (stages I-II: 23-39% (< 60 years), 16-31% (60-69 years), and 17-30% (≥ 70 years); stages III-IV: 5-19% (< 70 years) and 2-14% (≥ 70 years)). Perioperative survival also decreased with advancing stage and older age (stages I-II: 98-100% (< 60 years), 97-99% (60-69 years), and 94-99% (≥ 70 years); stages III-IV: 94-99% (< 70 years) and 81-96% (≥ 70 years)). Between 2003 and 2005 and 2009-2011, for overall PaC, both short-term and long-term survival improvements were observed in all countries except Belgium; for resected disease, short-term improvements were present only in the USA and Slovenia, but long-term improvements were observed in all countries except Slovenia, with stage-specific variations.Our large international study provides TNM stage- and age-specific population-based survival in overall and resected PaC that will facilitate clinical counseling. While the survival expectations for patients with resected PaC are substantially higher than the widely available and known dismal survival predictions for overall patients, conclusions on the benefits of resection cannot be made from this observational study. Patients with advanced-stage disease and/or older age should undergo careful risk assessment before treatment. Limited but inspiring improvement in survival is observed.
000136916 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000136916 588__ $$aDataset connected to CrossRef, PubMed,
000136916 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000136916 7001_ $$0P:(DE-HGF)0$$aBalavarca, Yesilda$$b2
000136916 7001_ $$0P:(DE-HGF)0$$aBabaei, Masoud$$b3
000136916 7001_ $$avan der Geest, Lydia$$b4
000136916 7001_ $$aLemmens, Valery$$b5
000136916 7001_ $$aVan Eycken, Liesbet$$b6
000136916 7001_ $$aDe Schutter, Harlinde$$b7
000136916 7001_ $$aJohannesen, Tom B$$b8
000136916 7001_ $$aPrimic-Žakelj, Maja$$b9
000136916 7001_ $$aZadnik, Vesna$$b10
000136916 7001_ $$aBesselink, Marc G$$b11
000136916 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b12$$udkfz
000136916 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b13$$eLast author$$udkfz
000136916 773__ $$0PERI:(DE-600)2131669-7$$a10.1186/s12916-018-1120-9$$gVol. 16, no. 1, p. 125$$n1$$p125$$tBMC medicine$$v16$$x1741-7015$$y2018
000136916 909CO $$ooai:inrepo02.dkfz.de:136916$$pVDB
000136916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)448ff49e51672d79b4747339ac15c898$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000136916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000136916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000136916 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000136916 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000136916 9141_ $$y2018
000136916 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC MED : 2015
000136916 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136916 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136916 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136916 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000136916 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000136916 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000136916 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136916 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136916 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136916 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136916 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136916 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136916 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136916 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136916 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBMC MED : 2015
000136916 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000136916 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000136916 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000136916 980__ $$ajournal
000136916 980__ $$aVDB
000136916 980__ $$aI:(DE-He78)C070-20160331
000136916 980__ $$aI:(DE-He78)G110-20160331
000136916 980__ $$aI:(DE-He78)L101-20160331
000136916 980__ $$aUNRESTRICTED